

Cell Line-Derived Xenograft (CDX) Tumor Models

- A large collection of cell line-derived xenograft (CDX) tumor models
 - » 215 validated models, SOC data available
- World leading imaging based orthotopic/metastatic CDX platform
 - » 28 models covering 16 tumor types

Cell Line-Derived Xenograft (CDX) tumor models: 215 models covering 25 cancer types

Tumor types	Cell lines
Bladder (7)	T24/83, RT112/84, UM-UC-3, J82, HT1197, KU-19-19, VM-CUB1
Brain (5)	U87*, LN-229*, D283*, T98G*, U118MG
Breast (20)	Cal51*, BT-474*, HCC1954*, MDA-MB-231*, MDA-MB-468*, HCC1806*, MCF7*, HCC1937, MDA-MB-436*, SUM-52PE, JIMT-1*, MDA-MB-361*, HCC-70, SUM159PT, MFM-223, T47D*, HCC1428, ZR-75-1*, MT-3, DU4475*
Cervical (2)	SW756, Ca Ski
Colorectal (19)	Colo205*, HT29*, HCT-116*, HCT-15*, LS180*, LS174T*, SW620*, HT55*, DLD-1, Lovo*, COLO-320DM, RKO, Caco-2, T84, WiDr, SW480, SW 48, LS411N, COLO 201
Duodenal (1)	HuTu80
Esophageal (2)	T.Tn, OE21*
Gastric (8)	NUGC4*, SNU-1*, SNU-16*, MGC-803, NCI-N87*, SNU-5, MKN45*, HS 746T
Head & Neck (4)	Cal 27, RPMI2650, SCC-9, Fadu*
Leukemia (13)	HEL 92.1.7*, MV4-11*, CCRF-CEM, HL-60, K562, KG-1, MOLT-4, Kasumi-1*, Nalm-6*, THP-1, SET-2, PL-21, MKL-1
Lymphoma (21)	Daudi*, SU-DHL-2*, SU-DHL-4*, SU-DHL-6, SU-DHL-10, Granta-519, Maver-1, Mino*, NAMALWA, Raji*, Ramos*, RL, WSU-DLCL2*, Z-138, U937, DoHH2*, Farage*, Pfeiffer, REC-1*, U2932, Toledo
Testicular Embryonal (1)	NEC14

*: validated with SOC compound

Tumor types	Cell lines
Liver (10)	BEL-7404*, Hep3B*, Huh 7*, HepG2, SNU-182, QGY-7703, SNU-398, JHH-7*, MHCC97H*, SK-HEP-1*
Lung (48)	NCI-H1650, NCI-H226, NCI-H460, PC9*, A549*, Calu-1, Calu-6*, EBC-1, A427*, NCI-H647, MSTO-211H, NCI-H292*, NCI-H322, NCI-H358*, NCI-H441*, NCI-H520, NCI-H1975*, NCI-H2228*, SK-MES-1, NCI-H1299, HCC-827*, HCC4006, NCI-H1703, NCI-H727, NCI-H2122*, DV-90, NCI-H69*, NCI-H1417*, NCI-H446, NCI-H526*, NCI-H82, SHP-77, Calu-3*, NCI-H2170, NCI-H820*, NCI-H23, NCI-H1568, NCI-H1944, NCI-H2023, NCI-H2030, NCI-H2126, NCI-H838, NCI-H1838*, DMS114*, NCI-H211*, NCI-H209*, NCI-H2286, NCI-H596
Lung (Small cell, 10)	NCI-H69*, NCI-H1417*, NCI-H446, NCI-H526*, NCI-H82, SHP-77, DMS114*, NCI-H211*, NCI-H209*, NCI-H2286
Melanoma (6)	A375*, SK-MEL-24, SK-MEL-28, COLO 829*, SK-MEL-5, MDA-MB-435S, MeWo
Myeloma (7)	KMS-28BM, KMS-11, MOLP-8*, NCI-H929, RPMI 8226*, MM.1S*, OPM-2
Neuroblastoma (4)	CHP-134*, SK-N-AS*, BE(2)-C*, SH-SY5Y
Ovary (5)	A2780*, SK-OV-3*, ES-2*, OVCAR-3, TOV21G
Pancreas (9)	BxPC3*, Mia-pa-ca-2*, KP4*, PANC-1*, CAPAN-1, Panc 02.13*, AsPC-1, HPAC, HPAFII
Prostate (5)	PC-3*, DU145*, LNCap*, VCaP, 22RV1*
Renal (5)	786-O*, ACHN, Caki-1, SK-NEP-1, A498
Sarcoma (11)	HT1080, A673, KHOS/NP, 143B, SJS-1*, SAOS-2, A204, G401, Aska-SS, HS-SY-II, Yamato-SS
Skin (1)	A431*
Thyroid(1)	TT


28 Luciferase labeled Orthotopic/Metastatic CDX and Syngeneic Models

Tumor types	Cell lines
Brain (2)	U87-luc ^{0S} , LN-229-luc ^{0S}
Breast (2)	MCF-7-luc ^{0M,S} , MDA-MB-231-luc ^{0M,S}
Colorectal (3)	Colo205-luc ^{20M} , HT29-luc ^{20M} , HCT-116-luc ^{20M}
Gastric (2)	MGC-803-luc ^{0M} , NCI-N87
Leukemia (3)	K562-luc ^{0M} , MOLT-4-luc ^{0M} , Nalm-6-luc ^{0M}
Liver (2)	Hep3B-luc ^{0S} , BEL-7404-luc ^{0M,S}
Lung (2)	NCI-H460-luc ^{20M} , A549-luc ⁰

O: orthotopic model; M: metastatic model; S: validated with SOC

Tumor types	Cell lines
Ovarian (2)	A2780-cp-luc ^{0M} , SK-OV-3-luc ^{20M}
Pancreas (1)	BxPC3-luc ^{20M}
Prostate (2)	LNCaP-luc ^{20M} , PC-3M-luc ^{20M,S}
Renal (1)	ACHN-luc ^{20M}
Sarcoma (1)	HT-1080-luc ^{20M}
Murine (5)	4T1-luc ^{20M} , EL4-luc ^{20M} , P815-luc (i.v.), B16-F10-G5-luc (i.v.), A20-luc ^{0M,S}

Case study: Orthotopic/Metastatic breast cancer MDA-MB-231-luc



Suppression of primary tumor development and metastases by Bosutinib in MDA-MB-231-luc orthotopic model

